Kenneth Frazier Net Worth

The estimated Net Worth of Kenneth C Frazier is at least $158 Milion dollars as of 7 November 2022. Mr. Frazier owns over 235,769 units of Merck & Co Inc stock worth over $107,416,968 and over the last 15 years he sold MRK stock worth over $22,797,600. In addition, he makes $27,648,500 as Chairman of the Board, President a Chief Executive Officer at Merck & Co Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Frazier MRK stock SEC Form 4 insiders trading

Kenneth has made over 39 trades of the Merck & Co Inc stock since 2010, according to the Form 4 filled with the SEC. Most recently he exercised 235,769 units of MRK stock worth $27,045,062 on 7 November 2022.

The largest trade he's ever made was exercising 867,084 units of Merck & Co Inc stock on 28 October 2022 worth over $99,463,206. On average, Kenneth trades about 72,960 units every 55 days since 2009. As of 7 November 2022 he still owns at least 936,422 units of Merck & Co Inc stock.

You can see the complete history of Mr. Frazier stock trades at the bottom of the page.

Kenneth Frazier biography

Kenneth C. Frazier is Chairman of the Board, President and Chief Executive Officer of the Company. Mr. Frazier has broad managerial and operational expertise and deep institutional knowledge, as well as a track record of achievement, integrity and sound judgment demonstrated prior to, and during, his long tenure with Merck. In addition, his role as the Chair of the Board Affairs Committee of Exxon Mobil Corporation has provided him with important experience on governance issues facing public companies. ?Chairman and Chief Executive Officer (2011-present) ?President (2010-present), ?Executive Vice President and President, Global Human Health (2007-2010), Executive Vice President and General Counsel (2006-2007), Senior Vice President and General Counsel (1999-2006). Exxon Mobil Corporation (since 2009).

What is the salary of Kenneth Frazier?

As the Chairman of the Board, President a Chief Executive Officer of Merck & Co Inc, the total compensation of Kenneth Frazier at Merck & Co Inc is $27,648,500. There are no executives at Merck & Co Inc getting paid more.

How old is Kenneth Frazier?

Kenneth Frazier is 65, he's been the Chairman of the Board, President a Chief Executive Officer of Merck & Co Inc since 2011. There are 8 older and 19 younger executives at Merck & Co Inc. The oldest executive at Merck & Co Inc is Thomas Cech, 73, who is the Independent Director.

What's Kenneth Frazier's mailing address?

Kenneth's mailing address filed with the SEC is MERCK & CO., INC., 126 E. LINCOLN AVENUE, RAHWAY, NJ, 07065.

Insiders trading at Merck & Co Inc

Over the last 15 years, insiders at Merck & Co Inc have traded over $138,980,380 worth of Merck & Co Inc stock and bought 48,209 units worth $1,563,736 . The most active insiders traders include Wendell P Weeks, Kenneth C Frazier a Douglas M Jr Baker. On average, Merck & Co Inc executives and independent directors trade stock every 15 days with the average trade being worth of $5,050,222. The most recent stock trade was executed by Chirfi Guindo on 5 August 2024, trading 36,901 units of MRK stock currently worth $4,250,995.

What does Merck & Co Inc do?

Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of whom it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada.

Complete history of Mr. Frazier stock trades at Exxon Mobil a Merck & Co Inc

Merck & Co Inc executives and stock owners

Merck & Co Inc executives and other stock owners filed with the SEC include:

• Kenneth Frazier,
  Chairman of the Board, President, Chief Executive Officer
• Roger Perlmutter,
  Executive Vice President, President - Merck Research Laboratories
• Robert Davis,
  Executive Vice President, Global Services, Chief Financial Officer
• Sanat Chattopadhyay,
  Executive Vice President and President - Merck Manufacturing Division
• Jennifer Zachary,
  Executive Vice President, General Counsel, Corporate Secretary
• Kenneth C. Frazier,
  Exec. Chairman
• Robert M. Davis,
  Pres, CEO & Director
• Jennifer L. Zachary,
  Exec. VP, Gen. Counsel & Corp. Sec.
• Sanat Chattopadhyay,
  Exec. VP & Pres of Merck Manufacturing Division
• Thomas Cech,
  Independent Director
• Leslie Brun,
  Lead Independent Director
• Pamela Craig,
  Independent Director
• Thomas Glocer,
  Independent Director
• Paul Rothman,
  Independent Director
• Peter Wendell,
  Independent Director
• Inge Thulin,
  Independent Director
• Patricia Russo,
  Independent Director
• Mary Coe,
  Independent Director
• Kathy Warden,
  Independent Director
• Christine Seidman,
  Independent Director
• Michael Fleming,
  Senior Vice President, Chief Ethics and Compliance Officer
• Rita Karachun,
  Senior Vice President Finance - Global Controller
• Julie Gerberding,
  Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health
• Richard DeLuca,
  Executive Vice President, President - Merck Animal Health
• Franklin Clyburn,
  Executive Vice President, Chief Commercial Officer
• Michael Nally,
  Executive Vice President, Chief Marketing Officer
• Steven Mizell,
  Executive Vice President, Chief Human Resources Officer, Human Resources
• Cristal N. Downing,
  Exec. VP and Chief Communications & Public Affairs Officer
• Michael W. Fleming,
  Sr. VP and Chief Ethics & Compliance Officer
• Peter Dannenbaum,
  VP of Investor Relations
• Jennifer Mauer,
  VP of Global Communications
• Peter Dannenbaum CFA,
  VP of Investor Relations
• David Michael Williams,
  Chief Information & Digital Officer
• Caroline Litchfield,
  Exec. VP & CFO
• Rochelle B Lazarus,
  Director
• Craig B. Thompson,
  Director
• Adam H Schechter,
  EVP & Pres-Global Human Health
• Adele D Ambrose,
  V-P & Chief Com. Officer
• Clark Golestani,
  EVP & Chief Info Officer
• John H Noseworthy,
  Director
• Wendell P Weeks,
  Director
• Michael J Holston,
  EVP, Chief Ethics & Compl Ofcr
• Carlos E Represas,
  Director
• C Robert Kidder,
  Director
• Weir Mirian M Graddick,
  Exec. V-P, Human Resources
• Ashley Watson,
  SVP Chief Ethics & Com Officer
• Frank Clyburn,
  EVP & Pres ? Human Health
• James H Scholefield,
  EVP,Chief Info&Digital Officer
• Joseph Romanelli,
  President, Human Health Int?l
• Stephen Mayo,
  Director
• Dean Y Li,
  Executive VP & President, MRL
• David Michael Williams,
  EVP,Chief Info&Digital Officer
• William B Jr Harrison,
  Director
• Michael Rosenblatt,
  Exec V-P & Chief Med Officer
• John Canan,
  Senior V-P, Controller
• Stanley F Barshay,
  Exec V-P Consumer Health Care
• Willie A Deese,
  Exec. V-P and Pres., MMD
• Anne M Tatlock,
  Director
• Samuel O Md Thier,
  Director
• Mervyn Turner,
  Chief Strategy Officer
• Willam N Kelley,
  Director
• Richard S Iii Bowles,
  Exe V-P & Chief Compl Officer
• Peter S Kim,
  Exec. V-P and Pres., MRL
• Thomas E Shenk,
  Director
• Bridgette P Heller,
  Exe.VP & Pres.Con.Hlth.Care
• Raul E Kohan,
  Exe V-P & Pres, Animal Health
• Steven F Goldstone,
  Director
• Harry R Jacobson,
  Director
• Richard T Clark,
  Chairman, President and CEO
• Peter N Kellogg,
  Exec. V.P. & C.F.O
• Bruce N Kuhlik,
  Exec. V.P. and General Counsel
• Cuong V Do,
  EVP & Chief Strategy Officer
• J Chris Scalet,
  Exe. VP, Global Services & CIO
• Risa J Lavizzo Mourey,
  Director
• Johannes Jacobus Oosthuizen,
  President, U.S. Market
• Caroline Litchfield,
  EVP & CFO
• Lisa Le Cointe Cephas,
  SVP Chief Ethics & Com Officer
• Michael A Klobuchar,
  EVP - Chief Strategy Officer
• Arpa Garay,
  SVP Human Health Global Mktg.
• Cristal N Downing,
  Chief Comm. & Public Afrs Ofcr
• Douglas M Jr Baker,
  Director
• Chirfi Guindo,
  Chief Marketing Officer
• Dalton Smart,
  SVP Fin. - Global Controller
• Betty D Larson,
  EVP, Chief HR Officer